The portfolio of Egis is expanded with the development and production of active materials

Egis – which conducts research and development activities exclusively in Hungary and manufactures 100% of its products here – already years ago, with a series of conscious investments, began to build the capacities behind the new service: in the last decade, it has made investments in Hungary totaling over HUF 100 billion.

Among the developments, the active ingredient production modernization, which was implemented in two stages between 2015-2019, will be implemented in 2022 by the so-called It was supplemented by investments in the development and production of Highly Potent active ingredients. These preparations, which are used in the treatment of cancer and rheumatic arthritis, among other things, have significant biological activity even at very low doses.